Novocure Ltd Stock
Novocure Ltd Stock
A loss of -1.990% shows a downward development for Novocure Ltd.
For the coming years our community has positive and negative things to say abot the Novocure Ltd stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -1.990% | 11.707% | 12.652% | -76.475% | 7.285% | -89.787% | - |
| Ironwood Pharmaceuticals | - | -1.316% | 1.351% | -19.786% | -26.471% | -18.033% | - |
| Sage Therapeutics Inc. | 0.610% | -14.738% | -27.778% | -76.979% | -44.750% | -82.131% | - |
| Iovance Biotherapeutics Inc. | -17.160% | -19.684% | -12.954% | 46.348% | 30.379% | -53.346% | - |
News
Novocure Reports First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of